

## UCLPartners Transfers of value

In line with the Association of British HealthTech Industries (ABHI) code of ethical business conduct and Association of the British Pharmaceutical Industry (ABPI) code of practice, from April 2022 onwards, all Health Innovation Networks, including UCLPartners, have decided to disclose details of joint working agreements with industry, as well as any donations by non-profit making or charitable organisations (together known as ‘transfers of value’) on an annual basis as a minimum.

UCLPartners programme	Background and need	Organisations involved	In-kind benefit or value received	Dates covered	Summary of in-kind benefit or value received	Health Innovation Network owner
Student mental health	UCLPartners and Koa Health piloted a new service, called Mind Your Mood, for students at UCL who needed support with their mental health. Mind Your Mood helped students better understand their mental health and helped them choose appropriate support services, if necessary. The service was developed in conjunction with clinical academics within UCL PALS, the student wellbeing service at UCL and clinicians at Camden and Islington Foundation Trust.	Koa Health	£10,000 worth of project management support	July 2021 to Feb 22		Peter Fonagy
CVD ACTION	<p>CVD PREVENT is a national primary care audit that uses data extracted from GP records. It supports health and care systems to understand how many people with cardiovascular disease (CVD) or conditions that lead to a higher risk of developing CVD are potentially not identified, undiagnosed, under-treated or possibly over-treated.</p> <p>CVD ACTION, developed by UCLPartners, will enable GP practices to act on CVD PREVENT data and optimise treatment in individual patients to prevent heart attacks and strokes. CVD ACTION will be embedded in GP IT systems and align with key CVD PREVENT indicators. It will automatically identify individuals and groups of patients with single or multiple risk factors (atrial fibrillation, high blood pressure, high cholesterol, type 2 diabetes, non-diabetic hyperglycaemia and chronic kidney disease) and identify gaps in management so that their care can be optimised. CVD ACTION will be free of charge to use and is expected to be available via the UCLPartners website.</p>	Boehringer Ingelheim (£100,000) AstraZeneca (£80,000)	£180,000 in total	April 2021 – March 24	Funding for UCLPartners to develop CVD ACTION; this was an industry grant and industry partners had no input into development of the tool	Matt Kearney

UCLPartners programme	Background and need	Organisations involved	In-kind benefit or value received	Dates covered	Summary of in-kind benefit or value received	Health Innovation Network owner
Anchors Measurement Framework	The UCLPartners Anchor Measurement Toolkit provides guidance and support to local health anchors and their partners, helping them to capture their activity and impact.	Health Foundation	£59,785	2022-23		Dominique Allwood
UCLPartners support services for International Accelerator programme (IAP)	<p>As part of international innovation exchange, and in support of partners such as Department for Business and Trade, UCLPartners will be providing support services and expertise as a delivery partner for this IAP, led by Health Innovation Consortium. The complexity of approaching and navigating the UK health &amp; care eco-system is often a significant barrier for international organisations, despite having solutions/innovations that would meet a need for the NHS.</p> <p>We have established an SLA based on our enhanced Health Innovation Network support offer and will provide this as part of a schedule of activities, in addition to responding to a needs assessment of each SME.</p>	Health Innovation Consortium (HIC)	HIC will fund up to £10,000 per IAP cohort, related to calling off services from our SLA.	Mar 2023 – Mar 24	Funding to support market access expertise to high-potential international innovations.	Fiona Sweny
Developing a new hospital medicines provision model in collaboration with Pfizer Ltd and Alliance Healthcare	<p>The COVID-19 pandemic introduced unprecedented rapid change in the NHS resulting in:</p> <ul style="list-style-type: none"> <li>• A widespread shift to remote management, reducing face-to-face appointments</li> <li>• Surging clinical demand linked to coronavirus infection</li> <li>• Severe disruption to routine practice in all clinical areas, e.g. cancer and long-term conditions</li> <li>• Problematic access to medicines, that would normally be prescribed and dispensed by the hospital outpatient pharmacy</li> </ul> <p>UCLPartners will collaborate with Pfizer &amp; Alliance Healthcare in a two-phased approach to explore and develop a new outpatient hospital medicines provision model:</p> <p>Phase 1 – Will involve local engagement and stakeholder roundtables over a period of 6 months, allowing for system input, co-design and sourcing of partners interested in piloting alternative medicines provision models.</p>	Pfizer Alliance Healthcare	<p>Pfizer will provide £49,200 to support funding for UCLPartners to employ a part time Senior Pharmacist to run the project. In addition, 63 hours of Pfizer colleagues' time will be provided to support the project.</p> <p>Alliance Healthcare will provide £7,500 for UCLPartners to</p>	Mar 2023 – Sept 23	Funding to support the development of new pathways that utilize the capacity and clinical competencies in community pharmacy to reduce pressures on hospital outpatient pharmacy and improve access for patients to medicines and treatments.	Fiona Sweny

UCLPartners programme	Background and need	Organisations involved	In-kind benefit or value received	Dates covered	Summary of in-kind benefit or value received	Health Innovation Network owner
			employ a part time Senior Pharmacist to run the project. In addition, 63 hours of Alliance Healthcare colleagues' time will be provided to support the project.			
Personalised Holistic Support Learning Programme	We are working with Macmillan Cancer Support to increase access to personalised holistic support, including support for financial, emotional or practical needs, for people diagnosed with cancer, so they can stay in treatment and keep their lives on track.	Macmillan Cancer Support	£307,230	2023-24		Rachel Penniston
CVD Academy	<p>UCLPartners CVD Academy aims to reduce heart attacks and strokes by developing a network of people who have the enthusiasm and drive to lead change within CVD.</p> <p>The CVD Academy, funded by Daiichi Sankyo, has launched across North Central London, North-East London and Mid &amp; South Essex. The Academy will support participants to implement their own CVD-focused transformation project.</p>	Daiichi Sankyo	£130,000	2023-24		Laura Boyd

Transfers of value 2022/23